All In MedTech

FDA Clearance Tracker · P130001

Epi proColon

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Apr 12, 2016 (this decision)Source: openFDAMethods & limitations

PMA

The decision

FDA number
P130001
Device name
Epi proColon
Applicant location
Knoxville, TN
Received
Jan 3, 2013
Decided
Apr 12, 2016
Decision
Approved
Expedited review
Yes, flagged as expedited in FDA's record.
Supplements
6 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code PHP

FDA's approval statement

As written in FDA's record.

The Epi proColon test is a qualitative in vitro diagnostic test for the detection of methylated Septin 9 DNA in EDTA plasma derived from patient whole blood specimens. Methylation of the target DNA sequence in the promoter region of the SEPT9_v2 transcript has been associated with the occurrence of colorectal cancer (CRC). The test uses a real-time polymerase chain reaction (PCR) with a fluorescent hydrolysis probe for the methylation specific detection of the Septin 9 DNA target. The Epi proColon test is indicated to screen adults of either sex, 50 years or older, defined as average risk for CRC, who have been offered and have a history of not completing CRC screening. Tests that are available and recommended in the USPSTF 2008 CRC screening guidelines should be offered and declined prior to offering the Epi proColon test. Patients with a positive Epi proColon test result should be referred for diagnostic colonoscopy. The Epi proColon test results should be used in combination with physician's assessment and individual risk factors in guiding patient management.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code PHP. The earliest in FDA's data is P130017, decided Aug 11, 2014.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for New Day Diagnostics, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.